FBLG Q2 2025 Earnings — FibroBiologics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

FBLGFibroBiologics, Inc. Common Stock

$17M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$5M

EPS (Diluted)

$-0.12

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$729,000

Balance Sheet

Total Assets

$14M

Total Liabilities

$13M

Stockholders' Equity

$860,000

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$4M	-$3M	-39.3%
Net Income	-$5M	$898,000	-618.7%